Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies
can result in severe side effects that some patients will not tolerate. AVI-4065 Injection is
a new drug designed to prevent the virus from reproducing in the body. We tested this drug in
healthy adult volunteers to optimize the dosing regimen, and are now proceeding in adult
patients with chronic active hepatitis C infections. Patients who have the disease and who
have had treatment but without success, will be recruited for the study.
The treatment of HCV patients initially consisted of subcutaneous injections given twice a
day for 14-days. Treatment arms of 28 days, twice or three-times per day have been added.